Literature DB >> 15278274

[Botulinum toxin A in the treatment of infantile cerebral palsy. Taking into account multilevel, integrated treatment].

G Molenaers1, K Desloovere, J De Cat.   

Abstract

Botulinum toxin A represents a significant development in the management of children and adolescents with spastic cerebral palsy. Prerequisites for an adequate result are a correct indication, an exact injection technique and an intensive post-treatment programme. Spastic muscle overactivity and the constant tendency of the involved muscles to shorten with growth cannot be treated by only one method. Therefore a multilevel approach and an integrated treatment schedule including plaster of Paris, orthoses and physiotherapy are currently the best ways to modify the disease process. The inclusion of objective clinical documentation techniques combined with 3-D instrumented gait analysis allows the determination of the indications more exactly and for monitoring the post-treatment results. If started early and correctly, this integrated management approach has the potential to modify the natural history of the disorder, and to reduce the frequency of later surgery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278274     DOI: 10.1007/s00132-004-0688-2

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  32 in total

1.  Gait pattern in patients with spastic diplegic cerebral palsy who underwent staged operations.

Authors:  G Fabry; X C Liu; G Molenaers
Journal:  J Pediatr Orthop B       Date:  1999-01       Impact factor: 1.041

2.  Electromyographic characteristics at the onset of independent walking in infancy.

Authors:  T Okamoto; K Okamoto
Journal:  Electromyogr Clin Neurophysiol       Date:  2001 Jan-Feb

3.  Adaptive changes in locomotor activity following botulinum toxin injection in ankle extensor muscles of cats.

Authors:  J E Misiaszek; K G Pearson
Journal:  J Neurophysiol       Date:  2002-01       Impact factor: 2.714

Review 4.  Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.

Authors:  K R Aoki; B Guyer
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

5.  A comparison of intensive neurodevelopmental therapy plus casting and a regular occupational therapy program for children with cerebral palsy.

Authors:  M Law; D Russell; N Pollock; P Rosenbaum; S Walter; G King
Journal:  Dev Med Child Neurol       Date:  1997-10       Impact factor: 5.449

6.  A pilot evaluation of conductive education-based intervention for children with cerebral palsy: the Tongala project.

Authors:  G J Coleman; J A King; D S Reddihough
Journal:  J Paediatr Child Health       Date:  1995-10       Impact factor: 1.954

Review 7.  Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.

Authors:  H K Graham; K R Aoki; I Autti-Rämö; R N Boyd; M R Delgado; D J Gaebler-Spira; M E Gormley; B M Guyer; F Heinen; A F Holton; D Matthews; G Molenaers; F Motta; P J García Ruiz; J Wissel
Journal:  Gait Posture       Date:  2000-02       Impact factor: 2.840

8.  Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.

Authors:  P J Flett; L M Stern; H Waddy; T M Connell; J D Seeger; S K Gibson
Journal:  J Paediatr Child Health       Date:  1999-02       Impact factor: 1.954

9.  Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function.

Authors:  D L Damiano; J Quinlivan; B F Owen; M Shaffrey; M F Abel
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

10.  The effects of neurodevelopmental treatment versus practice on the reaching of children with spastic cerebral palsy.

Authors:  L Fetters; J Kluzik
Journal:  Phys Ther       Date:  1996-04
View more
  1 in total

Review 1.  [Botulinum toxin therapy in orthopaedics].

Authors:  L Döderlein
Journal:  Orthopade       Date:  2006-01       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.